1
|
Zhang C, Shao H, Han Z, Liu B, Feng J, Zhang J, Zhang W, Zhang K, Yang Q, Wu S. Development and In Vitro-In Vivo Correlation Evaluation of IMM-H014 Extended-Release Tablets for the Treatment of Fatty Liver Disease. Int J Mol Sci 2023; 24:12328. [PMID: 37569704 PMCID: PMC10418331 DOI: 10.3390/ijms241512328] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 07/27/2023] [Accepted: 07/31/2023] [Indexed: 08/13/2023] Open
Abstract
This study aimed to develop extended-release tablets containing 25 mg IMM-H014, an original drug formulated by a direct powder pressing method based on pharmaceutical-grade hydrophilic matrix polymers such as hydroxypropyl methylcellulose, to establish an in vitro-in vivo correlation (IVIVC) to predict bioavailability. The tablets' mechanical properties and in vitro and in vivo performance were studied. The formulation was optimized using a single-factor experiment and the reproducibility was confirmed. The in vitro dissolution profiles of the tablet were determined in five dissolution media, in which the drug released from the hydrophilic tablets followed the Ritger-Peppas model kinetics in 0.01 N HCl medium for the first 2 h, and in phosphate-buffered saline medium (pH 7.5) for a further 24 h. Accelerated stability studies (40 °C, 75% relative humidity) proved that the optimal formulation was stable for 6 months. The in vivo pharmacokinetics study in beagle dogs showed that compared to the IMM-H014 immediate release preparation, the maximum plasma concentration of the extended-release (ER) preparation was significantly decreased, while the maximum time to peak and mean residence time were significantly prolonged. The relative bioavailability was 97.9% based on the area under curve, indicating that the optimal formulation has an obvious ER profile, and a good IVIVC was established, which could be used to predict in vivo pharmacokinetics based on the formulation composition.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Qingyun Yang
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; (C.Z.); (H.S.); (Z.H.); (B.L.); (J.F.); (J.Z.); (W.Z.); (K.Z.)
| | - Song Wu
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China; (C.Z.); (H.S.); (Z.H.); (B.L.); (J.F.); (J.Z.); (W.Z.); (K.Z.)
| |
Collapse
|
2
|
Xun M, Guo H, Cui Q, Zhang G, Feng Z, Gui L, Zhai L. Process Validation and in vitro- in vivo Evaluation of rosuvastatin calcium Tablets. Drug Dev Ind Pharm 2022; 48:140-145. [PMID: 35822245 DOI: 10.1080/03639045.2022.2101061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Establishing documented evidence which provides a high degree of assurance that a specific wet granulation process for manufacturing of rosuvastatin calcium tablets 40mg will consistently produce a product meeting its pre-determined specifications and quality attributes. It mainly involves the steps to be followed to evaluate and qualify the acceptability of the wet granulation manufacturing process of rosuvastatin calcium Tablets 40mg. The process is limited to the three batches manufactured of specific batch size with specified equipment and control parameters for rosuvastatin calcium tablets 40mg. The results suggest providing documentary evidence that all the manufactured rosuvastatin calcium tablets were evaluated as per specifications. The steps involved such as Blend uniformity results between 90% - 110%, compression assay results between 90%-110% were found within acceptable limits. Other tests related to compression such as hardness, thickness, disintegration, dissolution and for coatings such as weight gain, dissolution was found within acceptable limit.The design was choosed for fasting and fed study and showed bioequivalence with RLD (Codine ®), 90% CI values found to be between 80%-125%.
Collapse
Affiliation(s)
- Mingjin Xun
- National Engineering and Technology Research Center of Chirality Pharmaceutical, Lunan Pharmaceutical Group Co., Ltd., Linyi 276000.,International Pharmaceutical Engineering Lab. in Shandong Province, Shandong New Time Pharmaceutical Co., Ltd., Linyi 273400
| | - Hui Guo
- National Engineering and Technology Research Center of Chirality Pharmaceutical, Lunan Pharmaceutical Group Co., Ltd., Linyi 276000.,International Pharmaceutical Engineering Lab. in Shandong Province, Shandong New Time Pharmaceutical Co., Ltd., Linyi 273400
| | - Qingyan Cui
- National Engineering and Technology Research Center of Chirality Pharmaceutical, Lunan Pharmaceutical Group Co., Ltd., Linyi 276000.,International Pharmaceutical Engineering Lab. in Shandong Province, Shandong New Time Pharmaceutical Co., Ltd., Linyi 273400
| | - Guimin Zhang
- National Engineering and Technology Research Center of Chirality Pharmaceutical, Lunan Pharmaceutical Group Co., Ltd., Linyi 276000.,International Pharmaceutical Engineering Lab. in Shandong Province, Shandong New Time Pharmaceutical Co., Ltd., Linyi 273400
| | - Zhong Feng
- National Engineering and Technology Research Center of Chirality Pharmaceutical, Lunan Pharmaceutical Group Co., Ltd., Linyi 276000.,International Pharmaceutical Engineering Lab. in Shandong Province, Shandong New Time Pharmaceutical Co., Ltd., Linyi 273400
| | - Lei Gui
- National Engineering and Technology Research Center of Chirality Pharmaceutical, Lunan Pharmaceutical Group Co., Ltd., Linyi 276000.,International Pharmaceutical Engineering Lab. in Shandong Province, Shandong New Time Pharmaceutical Co., Ltd., Linyi 273400
| | - Liying Zhai
- National Engineering and Technology Research Center of Chirality Pharmaceutical, Lunan Pharmaceutical Group Co., Ltd., Linyi 276000.,International Pharmaceutical Engineering Lab. in Shandong Province, Shandong New Time Pharmaceutical Co., Ltd., Linyi 273400
| |
Collapse
|
3
|
Zhang F, Zhou Y, Wu N, Jia R, Liu A, Liu B, Zhou Z, Hu H, Han Z, Ye X, Ding Y, He Q, Wang H. In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation. Eur J Pharm Sci 2020; 157:105618. [PMID: 33122011 DOI: 10.1016/j.ejps.2020.105618] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2020] [Revised: 10/09/2020] [Accepted: 10/19/2020] [Indexed: 11/18/2022]
Abstract
AIM The waiver of bioequivalence (BE) studies is well accepted for Biopharmaceutics Classification System (BCS) class I drugs in form of immediate-release solid oral products. This study aimed to assess whether the rapid dissolution profiles (≥85% in 30 min) was crucial to guarantee bioequivalence of isosorbide mononitrate (ISMN) and then established a clinically relevant dissolution specification (CRDS) for screening BE or non-BE batches. METHOD A physiologically based pharmacokinetic (PBPK) model was constructed by integrating clinical and non-clinical data by B2O simulator. The model was verified by an actual clinical study (NMPA registration number: CTR20191360) with 28 healthy Chinese subjects. Then a virtual BE study was simulated to evaluate the bioequivalence of 7 virtual batches of ISMN tablets with different dissolution profiles, and the CRDS was established by integrating the results. RESULT The simulated PK behavior of ISMN was comparable to the observed. Even though the batches with slower dissolution were not equivalent to a rapid dissolution profile (≥85% in 30 min), it was demonstrated these batches would exhibit the similar in vivo performance. Meanwhile, the in vitro dissolution specification time point and the percentage of drug release (75% in 45 min) proved to have clinical relevance. CONCLUSION The virtual BE simulation by integrating in vitro dissolution profiles into the PBPK model provided a powerful tool for screening formulations, contributing to gaining time and reducing costs in BE evaluations.
Collapse
Affiliation(s)
- Fan Zhang
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing 100730, China
| | - Yinping Zhou
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing 100730, China
| | - Ni Wu
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing 100730, China
| | - Ranran Jia
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing 100730, China
| | - Aijing Liu
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing 100730, China
| | - Bo Liu
- Wuhan Institute of Technology, Hubei 430205, China
| | - Zhou Zhou
- Livzon Pharmaceutical Group Inc, Guangdong 519020, China
| | - Haitang Hu
- Livzon Pharmaceutical Group Inc, Guangdong 519020, China
| | - Zhihui Han
- Livzon Pharmaceutical Group Inc, Guangdong 519020, China
| | - Xiang Ye
- Hubei Yinghan Pharmaceutical Technology Co., Ltd, Hubei 435000, China
| | - Ying Ding
- Wuxi People's Hospital of Nanjing Medical University, Jiangsu 214023, China
| | - Qing He
- Wuxi People's Hospital of Nanjing Medical University, Jiangsu 214023, China
| | - Hongyun Wang
- Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Beijing 100730, China.
| |
Collapse
|
4
|
Jiang S, Zhang G, Wang L, Zeng Y, Liu W, Cheng Z. Development of a Two-Compartment System In vitro Dissolution Test and Correlation with In vivo Pharmacokinetic Studies for Celecoxib. AAPS PharmSciTech 2020; 21:59. [PMID: 31912248 DOI: 10.1208/s12249-019-1612-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Accepted: 12/14/2019] [Indexed: 02/07/2023] Open
Abstract
The objective of this study was to develop a novel open-mode two-compartment system dissolution apparatus to simulate the dissolution and absorption of poorly soluble drugs and to establish an in vitro-in vivo correlation (IVIVC). Celecoxib (CEB) was selected as a model drug, and in vitro dissolution was performed using the novel dissolution apparatus with acetate buffers at pH 4.5 containing Tween 80 (0.15%, w/v), at a flow rate of 30 mL/min and an agitation rate of 50 rpm. Cumulative release of all formulations was incomplete at approximately 70-80%, which likely reflected in vivo dissolution. Corresponding pharmacokinetic studies were performed in which twelve healthy male subjects from two bioequivalence studies received either one immediate release (IR) dose of the test (test 1 or test 2) or the reference formulation (Celebrex®, 200 mg). Individual plasma profiles of the formulations were deconvoluted via the Wanger-Nelson method to obtain the mean absorption fractions. A level A correlation was successfully developed with a good R2. The Weibull equation was used to describe the in vitro dissolution and in vivo absorption kinetics. In vitro dissolution correlated with in vivo absorption was applied successfully to predict the in vivo plasma concentrations-time profiles of the CEB formulations. Compared with conventional methods, the novel dissolution device showed great potential for discriminating the dissolution between formulations and generic drugs, which may provide a tool for making in vivo predictions for next bioequivalence trials.
Collapse
|
5
|
Li Z, He X, Tian S, Feng G, Huang C, Xun M, Wu Z, Wang Y. Simultaneous Evaluation of Dissolution and Permeation of Oral Drug Solid Formulations for Predicting Absorption Rate-Limiting Factors and In Vitro-In Vivo Correlations: Case Study Using a Poorly Soluble Weakly Basic Drug. AAPS PharmSciTech 2019; 20:321. [PMID: 31650430 DOI: 10.1208/s12249-019-1544-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Accepted: 09/19/2019] [Indexed: 01/10/2023] Open
Abstract
Combined dissolution and permeation systems are designed to simultaneously assess the dissolution of a pharmaceutical dosage form and the permeation of dissolved drugs therefrom. However, there were still some limitations on predicting the possible absorption rate-limiting steps and improving the in vitro-in vivo correlation (IVIVC) of a complete dosage form. In this study, the modified biorelevant media with some solubilizers and pH modifiers were integrated into the drug dissolution/absorption simulating system (DDASS). Indapamide, a poorly soluble compound (pKa = 8.8), was selected to validate the applicability of the modified biorelevant media. The elution and permeation dynamics of indapamide were investigated by using appropriate solubilizing agents in the DDASS. The absorption behaviors were analyzed after oral administration of indapamide in beagle dogs. The absorption rate-limiting steps and IVIVCs were predicted from the dissolution-permeation-absorption dynamic parameters. As a result, the absorption fraction of indapamide in the FaSSIFmod of DDASS was estimated to be approximately 100%, in accordance with its high permeability. The ratios of permeation rate to elution rate were 2.55 and 3.34 for the immediate- and sustained-release tablets of indapamide, respectively, suggesting a dissolution rate-limiting absorption for indapamine. In addition, point-to-point correlations were established between in vitro elution and in vivo absorption by the nonlinear and linear regression analysis ways (r > 0.85). The findings indicate that DDASS is a promising technique to develop improved IVIVCs of a complete dosage form, and the FaSSIFmod is suitable to predict the possible absorption rate-limiting steps of poorly soluble drugs in DDASS.
Collapse
|
6
|
Shrivas M, Khunt D, Shrivas M, Choudhari M, Rathod R, Misra M. Advances in In Vivo Predictive Dissolution Testing of Solid Oral Formulations: How Closer to In Vivo Performance? J Pharm Innov 2019. [DOI: 10.1007/s12247-019-09392-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
7
|
Li Z, Liu J, Li Y, Du X, Li Y, Wang R, Lv C, He X, Wang B, Huang Y, Zhang D. Identify super quality markers from prototype-based pharmacokinetic markers of Tangzhiqing tablet (TZQ) based on in vitro dissolution/ permeation and in vivo absorption correlations. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2018; 45:59-67. [PMID: 29685365 DOI: 10.1016/j.phymed.2018.04.001] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Revised: 01/08/2018] [Accepted: 04/01/2018] [Indexed: 06/08/2023]
Abstract
BACKGROUND A quality marker (Q-marker) is defined as an inherent chemical compound that is used for the quality control of a drug. Its biological activities are closely related to safety and therapeutic effects. Generally, a multiple-component herbal medicine may have many Q-markers. We therefore proposed a concept of "super Q-marker" satisfying both the criterion of Q-markers and PK-markers to be used in more effective quality control of herbal medicine. PURPOSE The first aim was to find suitable prototype-based PK-markers from Tangzhiqing tablets (TZQ), a Chinese patent medicine. Then super Q-markers were expected to be identified from the prototype-based PK-markers based on an in vitro-in vivo correlation study. METHODS Potentially eligible prototype-based PK-markers were identified in a single- and multiple-dose pharmacokinetic study on TZQ in 30 healthy volunteers. The in vitro dissolution and permeation profiles of the prototype-based PK-markers of TZQ were evaluated by the physiologically-based drug dissolution/absorption simulating system (DDASS). An in vitro-in vivo correlation analysis was conducted between the dissolution/permeation behaviors in DDASS and the actual absorption profiles in human to test the transferability and traceability of the promising super Q-markers for TZQ. RESULTS In human, plasma paeoniflorin and nuciferine as prototype-based PK-markers exhibited the appropriate pharmacokinetic properties, including dose-dependent systemic exposure (AUC, Cmax) and a proper elimination half-life (1∼3h). In DDASS, it was predicted that paeoniflorin and nuciferine are highly permeable but the absorption rates are primarily limited by the dissolution rates. Moreover, the established in vitro-in vivo correlations of paeoniflorin and nuciferine were in support of the super Q-markers features. CONCLUSION Paeoniflorin and nuciferine are identified as the super Q-markers from the prototype-based PK-markers of TZQ based on findings from a combination of in vitro, in vivo, and in vitro-in vivo correlation studies. This method is practical for optimal identification of qualified Q-markers, thus helping improve the quality control of herbal medicines.
Collapse
Affiliation(s)
- Ziqiang Li
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China
| | - Jia Liu
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China; Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
| | - Yazhuo Li
- Tianjin Institute of Pharmaceutical Research, Tianjin 300193, China
| | - Xi Du
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China
| | - Yanfen Li
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China
| | - Ruihua Wang
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China
| | - Chunxiao Lv
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China
| | - Xin He
- Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
| | - Baohe Wang
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China
| | - Yuhong Huang
- Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300150, China.
| | - Deqin Zhang
- Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
| |
Collapse
|
8
|
Li ZQ, Tian S, Gu H, Wu ZG, Nyagblordzro M, Feng G, He X. In Vitro-In Vivo Predictive Dissolution-Permeation-Absorption Dynamics of Highly Permeable Drug Extended-Release Tablets via Drug Dissolution/Absorption Simulating System and pH Alteration. AAPS PharmSciTech 2018; 19:1882-1893. [PMID: 29663288 DOI: 10.1208/s12249-018-0996-1] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Accepted: 03/16/2018] [Indexed: 11/30/2022] Open
Abstract
Each of dissolution and permeation may be a rate-limiting factor in the absorption of oral drug delivery. But the current dissolution test rarely took into consideration of the permeation property. Drug dissolution/absorption simulating system (DDASS) valuably gave an insight into the combination of drug dissolution and permeation processes happening in human gastrointestinal tract. The simulated gastric/intestinal fluid of DDASS was improved in this study to realize the influence of dynamic pH change on the complete oral dosage form. To assess the effectiveness of DDASS, six high-permeability drugs were chosen as model drugs, including theophylline (pKa1 = 3.50, pKa2 = 8.60), diclofenac (pKa = 4.15), isosorbide 5-mononitrate (pKa = 7.00), sinomenine (pKa = 7.98), alfuzosin (pKa = 8.13), and metoprolol (pKa = 9.70). A general elution and permeation relationship of their commercially available extended-release tablets was assessed as well as the relationship between the cumulative permeation and the apparent permeability. The correlations between DDASS elution and USP apparatus 2 (USP2) dissolution and also between DDASS permeation and beagle dog absorption were developed to estimate the predictability of DDASS. As a result, the common elution-dissolution relationship was established regardless of some variance in the characteristic behavior between DDASS and USP2 for drugs dependent on the pH for dissolution. Level A in vitro-in vivo correlation between DDASS permeation and dog absorption was developed for drugs with different pKa. The improved DDASS will be a promising tool to provide a screening method on the predictive dissolution-permeation-absorption dynamics of solid drug dosage forms in the early-phase formulation development.
Collapse
|
9
|
Narayanasamy R, Shabaraya R. Development, Internal and External Validation of Naproxen Sodium Sustained Release Formulation: an Level A In Vitro-In Vivo Correlation. Turk J Pharm Sci 2017; 14:120-126. [PMID: 32454602 DOI: 10.4274/tjps.87587] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2016] [Accepted: 01/26/2017] [Indexed: 12/01/2022]
Abstract
Objectives The aim of the present study was to develop and validate an in vitro-in vivo correlation (IVIVC) for naproxen sodium-sustained release tablets and to compare their plasma concentrations over time with the immediate-release tablets. Materials and Methods In vitro release rate data were obtained for each tablet by using the USP Apparatus II, paddle stirrer at 50 rpm in pH 7.4 phosphate buffer. A four-way crossover study was conducted in 6 healthy subjects by administering naproxen sodium sustained release 375 mg and 500 mg of immediate release tablets. Series of blood samples were collected over 24 hours and estimated by using the validated liquid chromatography tandem-mass spectrometry method. Results The similarity factor was calculated and it was found that values between, 50 and 100 indicates similarity of the profiles. Assessment of predicted and observed bioavailability was performed and prediction errors (PE) % calculated, as per the Food Drug Administration guidelines, the average absolute PE% of Cmax and AUC of individual formulation was found below 15% for establishment of IVIVC, based on internal prediction strongly suggesting that the naproxen sodium IVIVC models are valid. During external validation the predicted curve for the naproxen sodium sustained-release tablets was found to be identical to immediate release tablets and considered as valid. Conclusion IVIVC can serve as a surrogate for in vivo bioavailability study and supports biowaivers, supports and validates the dissolution methods and specification settings and assists in quality control during scale-up and post-approval changes. It may be used to predict the variation in site change, process changes and to predict the absorption performance of naproxen sodium products with different release rates.
Collapse
|
10
|
Deng J, Staufenbiel S, Hao S, Wang B, Dashevskiy A, Bodmeier R. Development of a discriminative biphasic in vitro dissolution test and correlation with in vivo pharmacokinetic studies for differently formulated racecadotril granules. J Control Release 2017; 255:202-209. [DOI: 10.1016/j.jconrel.2017.04.034] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 04/20/2017] [Accepted: 04/24/2017] [Indexed: 11/25/2022]
|
11
|
Dynamic dissolution-/permeation-testing of nano- and microparticle formulations of fenofibrate. Eur J Pharm Sci 2017; 96:20-27. [DOI: 10.1016/j.ejps.2016.09.001] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Revised: 08/26/2016] [Accepted: 09/01/2016] [Indexed: 11/18/2022]
|
12
|
Generic sustained release tablets of trimetazidine hydrochloride: Preparation and in vitro–in vivo correlation studies. Asian J Pharm Sci 2016. [DOI: 10.1016/j.ajps.2015.10.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
13
|
Al Durdunji A, AlKhatib HS, Al-Ghazawi M. Development of a biphasic dissolution test for Deferasirox dispersible tablets and its application in establishing an in vitro–in vivo correlation. Eur J Pharm Biopharm 2016; 102:9-18. [DOI: 10.1016/j.ejpb.2016.02.006] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Revised: 02/04/2016] [Accepted: 02/10/2016] [Indexed: 11/29/2022]
|
14
|
Zhou Y, Chu W, Lei M, Li J, Du W, Zhao C. Application of a continuous intrinsic dissolution–permeation system for relative bioavailability estimation of polymorphic drugs. Int J Pharm 2014; 473:250-8. [DOI: 10.1016/j.ijpharm.2014.07.012] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2014] [Revised: 06/16/2014] [Accepted: 07/07/2014] [Indexed: 10/25/2022]
|
15
|
Chemically cross-linked poly(acrylic-co-vinylsulfonic) acid hydrogel for the delivery of isosorbide mononitrate. ScientificWorldJournal 2013; 2013:340737. [PMID: 24250265 PMCID: PMC3821952 DOI: 10.1155/2013/340737] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Accepted: 09/10/2013] [Indexed: 11/18/2022] Open
Abstract
We report synthesis, characterization, and drug release attributes of a series of novel pH-sensitive poly(acrylic-co-vinylsulfonic) acid hydrogels. These hydrogels were prepared by employing free radical polymerization using ethylene glycol dimethacrylate (EGDMA) and benzyl peroxide (BPO) as cross-linker and initiator, respectively. Effect of acrylic acid (AA), polyvinylsulfonic acid (PVSA), and EGDMA on prepared hydrogels was investigated. All formulations showed higher swelling at high pHs and vice versa. Formulations containing higher content of AA and EGDMA show reduced swelling, but one with higher content of PVSA showed increased swelling. Hydrogel network was characterized by determining structural parameters and loaded with isosorbide mononitrate. FTIR confirmed absence of drug polymer interaction while DSC and TGA demonstrated molecular dispersion of drug in a thermally stable polymeric network. All the hydrogel formulations exhibited a pH dependent release of isosorbide mononitrate which was found to be directly proportional to pH of the medium and PVSA content and inversely proportional to the AA contents. Drug release data were fitted to various kinetics models. Results indicated that release of isosorbide mononitrate from poly(AA-co-VSA) hydrogels was non-Fickian and that the mechanism was diffusion-controlled.
Collapse
|
16
|
Yaro P, He X, Liu W, Xun M, Ma Y, Li Z, Shi X. In vitro–in vivocorrelations for three different commercial immediate-release indapamide tablets. Drug Dev Ind Pharm 2013; 40:1670-6. [DOI: 10.3109/03639045.2013.842577] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
17
|
Liu W, He X, Li Z, Gao X, Ma Y, Xun M, Liu C. Development of a Bionic System for the Simultaneous Prediction of the Release/Absorption Characteristics of Enteric-Coated Formulations. Pharm Res 2012; 30:596-605. [DOI: 10.1007/s11095-012-0905-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2012] [Accepted: 10/08/2012] [Indexed: 10/27/2022]
|
18
|
Hou J, He X, Xu X, Shi X, Xu Y, Liu C. Application of anin vitroDDASS to evaluate oral absorption of two chemicals simultaneously: establishment of a level Ain vitro–in vivocorrelation. Drug Dev Ind Pharm 2012; 38:1305-12. [DOI: 10.3109/03639045.2011.650642] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|